0.9949
전일 마감가:
$0.97
열려 있는:
$0.97
하루 거래량:
15,333
Relative Volume:
0.02
시가총액:
$6.57M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.49%
1개월 성능:
-26.30%
6개월 성능:
+59.11%
1년 성능:
+0.00%
Chromocell Therapeutics Corp Stock (CHRO) Company Profile
명칭
Chromocell Therapeutics Corp
전화
(917) 644-6313
주소
685 US HIGHWAY ONE, NORTH BRUNSWICK
CHRO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CHRO
Chromocell Therapeutics Corp
|
0.9949 | 6.79M | 0 | 0 | 0 | 0.00 |
![]()
ONC
Beigene Ltd Adr
|
240.40 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.89 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 41.82M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
595.26 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
73.67 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
Chromocell Therapeutics Corp 주식(CHRO)의 최신 뉴스
Channel Therapeutics Faces Financial Uncertainty as Auditors Issue Going Concern Warning - Stock Titan
Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings - Benzinga
Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks
Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - GlobeNewswire Inc.
Channel Therapeutics Corporation announced that it has received $0.25 million in funding -February 24, 2025 - Marketscreener.com
Channel Therapeutics secures $325,000 promissory note By Investing.com - Investing.com Australia
Channel Therapeutics secures $325,000 promissory note - Investing.com India
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
Wall Street-Heavily Traded - WDRB
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Channel Therapeutics Advances Novel Pain Treatment Strategy with NaV1.7 Inhibitor Pipeline - StockTitan
Channel Therapeutics' Pain Treatment Breakthrough: Novel Nerve Block Outperforms Standard Care in Key Trial - StockTitan
Chromocell Therapeutics Announces Name Change to Channel Therapeutics Corporation and Provides Therapeutic Program Updates - Defense World
Chromocell Announces Name Change to 'Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - The Manila Times
Chromocell changes name to Channel Therapeutics, provides program updates - TipRanks
Channel Therapeutics Corporation Provides Therapeutic Program Update - Marketscreener.com
Chromocell Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 - Marketscreener.com
Certain Warrants of Chromocell Therapeutics Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2024. - Marketscreener.com
Chromocell Therapeutics Corporation announces an Equity Buyback for $0.25 million worth of its shares. - Marketscreener.com
Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - Marketscreener.com
Chromocell Therapeutics Corporation announced that it expects to receive $0.75 million in funding - Marketscreener.com
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14 - Marketscreener.com
Chromocell Therapeutics Corporation Announces Formal Launch of Eye Pain Treatment Program - Marketscreener.com
Chromocell Therapeutics Corporation announced that it has received $0.75 million in funding - Marketscreener.com
Chromocell Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Channel Therapeutics finalizes corporate restructuring By Investing.com - Investing.com Canada
Channel Therapeutics finalizes corporate restructuring - Investing.com
Channel Therapeutics announces corporate restructuring - Investing.com
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times
Chromocell to Present at Upcoming Fall Investor Conferences - StockTitan
Chromocell Therapeutics amends stock repurchase plan - TradingPedia
Chromocell Announces Amendment to Stock Repurchase Plan | CHRO Stock News - StockTitan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - GlobeNewswire
Another Delaware Publicly Traded Company Proposes A Nevada Move | Allen Matkins - JD Supra
Chromocell to Participate in Life Sciences Investor Forum September 19th - Yahoo Finance
CDMO Benuvia Appoints Terry Novak As New CEO - Pharmaceutical Online
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Tranche Update on Channel Therapeutics Corporation's Equity Buyback Plan announced on August 7, 2024. - Marketscreener.com
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - TradingView
Chromocell Issues Letter to Stockholders from Chief Executive Officer - StockTitan
Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech
Are there bright times for biotech IPOs ahead? - European Biotechnology Magazine
Sidoti Events, LLC's Virtual March Small-Cap Conference - Yahoo Finance
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million - Stock Titan
CHRO Stock Price and Chart — AMEX:CHRO - TradingView
CHROChannel Therapeutics Corporation Latest Stock News & Market Updates - StockTitan
Chromocell Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Chromocell Therapeutics Corp (CHRO) 재무 분석
Chromocell Therapeutics Corp (CHRO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):